Earned Wealth Advisors LLC Invests $418,000 in Illumina, Inc. $ILMN

Earned Wealth Advisors LLC acquired a new position in Illumina, Inc. (NASDAQ:ILMN) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 4,386 shares of the life sciences company’s stock, valued at approximately $418,000.

Other hedge funds have also recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. raised its position in Illumina by 9.5% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 4,673 shares of the life sciences company’s stock worth $371,000 after buying an additional 404 shares during the last quarter. Vontobel Holding Ltd. raised its stake in Illumina by 109.6% during the 1st quarter. Vontobel Holding Ltd. now owns 12,451 shares of the life sciences company’s stock valued at $988,000 after buying an additional 6,510 shares during the last quarter. Keybank National Association OH boosted its stake in shares of Illumina by 0.8% in the 1st quarter. Keybank National Association OH now owns 395,066 shares of the life sciences company’s stock worth $31,345,000 after buying an additional 3,052 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in Illumina by 15.0% in the first quarter. Teacher Retirement System of Texas now owns 669,730 shares of the life sciences company’s stock valued at $53,136,000 after acquiring an additional 87,252 shares during the period. Finally, GF Fund Management CO. LTD. grew its stake in shares of Illumina by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 4,061 shares of the life sciences company’s stock valued at $322,000 after purchasing an additional 731 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 4.2%

Shares of ILMN opened at $99.01 on Friday. The firm has a market cap of $15.22 billion, a P/E ratio of 12.53, a price-to-earnings-growth ratio of 2.34 and a beta of 1.40. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a 50 day simple moving average of $97.97 and a two-hundred day simple moving average of $92.30.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company’s quarterly revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, equities analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of research reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Illumina in a report on Wednesday, October 8th. Evercore ISI reduced their price objective on Illumina from $135.00 to $132.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Citigroup downgraded Illumina from a “hold” rating to a “strong sell” rating and lowered their target price for the company from $85.00 to $80.00 in a research report on Wednesday, July 9th. Robert W. Baird set a $105.00 price objective on Illumina in a research report on Friday, October 24th. Finally, Barclays lifted their price target on shares of Illumina from $90.00 to $95.00 and gave the company an “underweight” rating in a report on Thursday, October 2nd. Five investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $115.25.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.